Although several studies have associated SOX4 expression with shorter survival in prostate cancer, gastric cancer, and colon cancer [7, 9, 10], this is the first to demonstrate the correlation between SOX4 expression and treatment failure in OSCC. This evidence concerns the gene SOX4 and prostate carcinoma.